Ballard Spahr represented OMERS Life Sciences on the deal. Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral…
OMERS Life Sciences’ $200 Million Acquisition of Portion of Global Royalties on MAVYRE
![](https://globallegalchronicle.com/wp-content/uploads/2023/05/Kenneth_sonnenfeld.png)